Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma
A Phase I/II, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Vactosertib as a Single Agent in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma
Sponsor: MedPacto, Inc.
Listed as NCT05588648, this PHASE1/PHASE2 trial focuses on Osteosarcoma and remains actively recruiting participants. Sponsored by MedPacto, Inc., it has been updated 10 times since 2023, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Recruiting PHASE1/PHASE2
-
May 2025 — Sep 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Apr 2025 — May 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Sep 2024 — Apr 2025 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
▶ Show 5 earlier versions
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2024 — Jun 2024 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
May 2023 — Feb 2024 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Mar 2023 — May 2023 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Nov 2022 — Mar 2023 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- MedPacto, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .